COVID-19 testing

Victory Square Portfolio Company, Hydreight Technologies Inc. Announces Start of Trading On The TSX Venture Exchange

Retrieved on: 
Thursday, December 1, 2022

The VST business model is focused on identifying opportunities early, mitigating risk and creating outsized returns.

Key Points: 
  • The VST business model is focused on identifying opportunities early, mitigating risk and creating outsized returns.
  • And, we believe that Hydreight is that outlier, said VST CEO Shafin Diamond Tejani.
  • Hydreight aims to empower pharmacies to provide their products to service providers in a direct and easily accessible manner.
  • "We couldn't be more thrilled to begin trading on the TSXV," Hydreight CEO Shane Madden said.

Hydreight Technologies Inc. Announces Start Of Trading On The TSX Venture Exchange

Retrieved on: 
Thursday, December 1, 2022

Hydreight Technologies Inc. has received final approval for its qualifying transaction as principally described in its filing statement dated November 10, 2022, from the TSX Venture Exchange.

Key Points: 
  • Hydreight Technologies Inc. has received final approval for its qualifying transaction as principally described in its filing statement dated November 10, 2022, from the TSX Venture Exchange.
  • Hydreight Technologies Inc. starts trading under the symbol 'NURS' on the TSX Venture Exchange at market open on December 1, 2022.
  • "We couldn't be more thrilled to begin trading on the TSXV," Hydreight CEO Shane Madden said.
  • On February 10, 2021, IV Hydreight Inc. was acquired by Victory Square Technologies Inc. (VST) (CSE:VST) (OTC:VSQTF).

OraSure Technologies Continues its Dedication to Ending the HIV Epidemic

Retrieved on: 
Thursday, December 1, 2022

OraSure has played a critical role in the fight against HIV globally since 2002.

Key Points: 
  • OraSure has played a critical role in the fight against HIV globally since 2002.
  • In 2012, the Company received FDA approval for the first, and still only, over-the-counter oral fluid HIV test, the OraQuick In-Home HIV Test.
  • The OraQuick In-Home HIV Test is the first and only oral fluid rapid over-the-counter (OTC) HIV test approved in the U.S.
  • The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.

Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index

Retrieved on: 
Wednesday, November 30, 2022

Following the inclusion of Prenetics, there will be a total of 17 HK-headquartered companies included in this Hong Kong index.

Key Points: 
  • Following the inclusion of Prenetics, there will be a total of 17 HK-headquartered companies included in this Hong Kong index.
  • According to MSCI, the entire MSCI Global Micro Cap index includes a total of 299 constituents in 22 developed markets (with Hong Kong included).
  • It is widely recognised as a benchmark for global institutional investors to optimise their investment portfolios especially passive index funds.
  • In addition, Prenetics' inclusion in the MSCI Global Micro Cap Index (Hong Kong) represents a key milestone and reflects the confidence of stakeholders in the Company's long term growth strategy.

Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index

Retrieved on: 
Wednesday, November 30, 2022

The Company plans to fund the repurchase program using existing cash and cash equivalents or future cash flow.

Key Points: 
  • The Company plans to fund the repurchase program using existing cash and cash equivalents or future cash flow.
  • Following the inclusion of Prenetics, there will be a total of 17 HK-headquartered companies included in this Hong Kong index.Accordingto MSCI, the entire MSCI Global Micro Cap index includesa total of 299 constituents in 22 developed markets (with Hong Kong included).
  • It is widely recognised as a benchmark for global institutional investors to optimise their investment portfolios especially passive index funds.
  • In addition, Prenetics inclusion in the MSCI Global Micro Cap Index (Hong Kong) represents a key milestone and reflects the confidence of stakeholders in the Companys long term growth strategy.

ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022

Retrieved on: 
Wednesday, November 30, 2022

GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022 at 2:30 pm EST.

Key Points: 
  • GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022 at 2:30 pm EST.
  • The Company provides traditional CLIA molecular laboratory services, including COVID-19 testing.
  • ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.
  • ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds.

Victory Square Announces Closing of Qualifying Transaction Involving Its Former Subsidiary, IV Hydreight, and Anticipated Trading Date for Resulting Issuer Shares

Retrieved on: 
Tuesday, November 29, 2022

VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Victory Square Technologies Inc. (CSE:VST) (OTC:VSQTF) ("VST" or the "Company") is pleased to announce that, further to its news release dated July 13, 2022, the reverse takeover transaction (the "Transaction") pursuant to a merger agreement dated effective July 12, 2022, as amended (the "Merger Agreement"), between the Company, IV Hydreight Inc. ("Hydreight"), Hydreight Technologies Inc. (formerly Perihelion Capital Ltd.) ("NURS"), 1362795 B.C. Ltd. ("AssetCo"), and 1203500 B.C. Ltd., a wholly-owned subsidiary of NURS, has completed.

Key Points: 
  • Additionally, NURS issued 1,394,841 NURS Shares at a deemed price of $0.63 per share to a third party as a finders fee for the Transaction.
  • Certain NURS Shares are subject to escrow pursuant to the policies of the TSX Venture Exchange (the "Exchange").
  • It is anticipated that the NURS Shares will resume trading on the Exchange under the trading symbol "NURS" on or about December 1, 2022.
  • Pursuant to the Transaction, VST sold its interest in Hydreight and now owns approximately 73.72% of the issued and outstanding NURS Shares.

Curative Appoints New Chief Marketing Officer

Retrieved on: 
Tuesday, November 29, 2022

Curative , a leading healthcare delivery company, today announced the appointment of Beth Henry to the position of new Chief Marketing Officer (CMO) of Curative.

Key Points: 
  • Curative , a leading healthcare delivery company, today announced the appointment of Beth Henry to the position of new Chief Marketing Officer (CMO) of Curative.
  • View the full release here: https://www.businesswire.com/news/home/20221128005785/en/
    Beth Henry has been named Chief Marketing Officer (CMO) of Curative, one of the nation's leading healthcare delivery companies.
  • Henry comes to Curative as a proven marketing executive with over two decades of healthcare brand marketing experience with some of the nation's most notable brands in healthcare.
  • (Photo: Business Wire)
    We are thrilled to have Beth on the Curative team as our new CMO, bringing her strong skill set of consumer healthcare-focused marketing and communications to our Marketing Communications team, said Fred Turner, CEO and co-founder of Curative.

G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements

Retrieved on: 
Tuesday, November 22, 2022

In accordance with Nasdaq Rule 5810(c)(2)(A), the Company has 45 calendar days, or until January 6, 2023, to submit a plan to regain compliance.

Key Points: 
  • In accordance with Nasdaq Rule 5810(c)(2)(A), the Company has 45 calendar days, or until January 6, 2023, to submit a plan to regain compliance.
  • The Company intends to evaluate its courses of action and to timely submit a plan to Nasdaq to regain compliance with the Nasdaq minimum shareholders equity requirement.
  • About G Medical Innovations Holdings Ltd.
    G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.
  • G Medical Innovations Holdings Ltd.

Lifshitz Law PLLC Announces Investigations of Oscar Health, Inc. (NYSE: OSCR), Upstart Holdings, Inc. (NASDAQ: UPST), C3.ai, Inc. (NYSE: AI), and TaskUs, Inc. (NASDAQ: TASK)

Retrieved on: 
Sunday, November 20, 2022

If you are an Oscar Health investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.

Key Points: 
  • If you are an Oscar Health investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • If you are an Upstart investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.
  • Prior results do not guarantee or predict a similar outcome with respect to any future matter.